We are live on ! Find out more
CLC

Charles-Lim Capital Portfolio holdings

AUM $319M
1-Year Est. Return 13.77%
This Fund
S&P 500
This Quarter Est. Return
+33.32%
1 Year Est. Return
-13.77%
3 Year Est. Return
+4.44%
5 Year Est. Return
-59.29%
10 Year Est. Return
+482.41%
AUM
$571M
AUM Growth
+$85.4M
Cap. Flow
-$53.6M
Cap. Flow %
-9.39%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IBN icon
ICICI Bank
IBN
+$34.8M
2
HDB icon
HDFC Bank
HDB
+$13.9M
3
RDY icon
Dr. Reddy's Laboratories
RDY
+$4.96M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 72.77%
2 Financials 27.23%
3 Healthcare 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SE icon
1
Sea Limited
SE
$71.8B
$415M 72.77%
12,497,402
HDB icon
2
HDFC Bank
HDB
$120B
$154M 26.97%
4,732,852
-459,944
-9% -$13.9M
IBN icon
3
ICICI Bank
IBN
$106B
$1.52M 0.27%
120,576
-3,000,000
-96% -$34.8M
RDY icon
4
Dr. Reddy's Laboratories
RDY
$10.1B
-611,990
Closed -$4.96M

Similar funds

Charles-Lim Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Charles-Lim Capital held 4 positions worth $571M, up 18% from $485M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Charles-Lim Capital withdrew a net $53.6M in Q2 2019, closing 1 position and reducing 2 holdings. Its most notable exit was Dr. Reddy's Laboratories, an estimated $4.96M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 73% of assets, up from 61% a quarter earlier, followed by Financials and Healthcare.

  • Charles-Lim Capital's biggest Q2 2019 reduction was ICICI Bank, cutting an estimated $34.8M.
  • Charles-Lim Capital fully exited Dr. Reddy's Laboratories in Q2 2019, selling an estimated $4.96M.
  • Charles-Lim Capital's ten largest holdings make up 100% of its $571M portfolio in Q2 2019.
  • Charles-Lim Capital opened 0 new positions and closed 1 in Q2 2019.
  • Charles-Lim Capital's portfolio value rose 18% quarter-over-quarter to $571M.

Based on Charles-Lim Capital's 13F filing for Q2 2019, filed 14 Aug 2019.